sitem-insel School offers university-level education taught by professors and lecturers from academia and industry.
sitem-insel Enabling Facilities provides infrastructure to foster cooperation between industrial partners, basic science, and clinic.
The mission of sitem-insel is to create and foster an enhanced environment for translational medicine in Switzerland. The strategy is based on three pillars:
university education for professionals in medical devices and life sciences industry
sitem-insel Enabling Facilities
specialized R&D workshops, laboratories, and equipment for industry, and academia
sitem-insel Promoting Services
promotes innovation and optimizes administrative and regulatory effort from bench to bedsides
sitem-insel aims to establish and operate a national center of competence for translational medicine in Berne
Translational medicine deals with the transition from new findings and products from industrial development and basic research to clinical application. This process-oriented discipline professionalizes the interaction between industry, universities, clinicians, regulatory bodies and investors.
sitem-insel is an independent, non-profit public-private partnership with the legal form of a public limited company. Government funding of appr. CHF 50m has been approved for the start-up phase. Subsequently, sitem-insel will be financially independent.
During the MDR Readiness Day, manufacturers will have the opportunity to exchange ideas, answer open questions themselves and find out important discussion areas for them in the areas of development, technical documentation, registration, and market surveillance. Topics to be analyzed in depth by industry representatives will be dealt with in the subsequent MDR Support Panel.
Own-brand-labeler (OBL), manufactures using hazardous substances, manufacturers of combination products or software developers will face many new challenges with the new MDR. Find out what you need to pay attention to in your products.
sitem-insel organizes together with its partners from University of Bern and from Universität Hamburg the first Open Strategy Paper Development Workshop on October 11, 2019. The keynote will be held by Richard Whittington from Saïd Business School, University of Oxford.
Conventional pacemakers have batteries which are responsible for the power supply of the device. These batteries have a finite energy storage capacity, which is why pacemaker generator changes are frequent due to battery exhaustion. Pacemakers without batteries are therefore highly desirable. Reoperations and resulting complications can thus be avoided. The following article by among others sitem-insel employee Dr. Adrian Zurbuchen gives an insight into the research and development activities in the field of battery-free pacemakers.
At the operational level, a handover will take place as planned on November 1, 2018. Dr. sc. nat. ETH Simon A. Rothen will take over the newly created CEO function from the former Managing Director Prof. em. Dr. med. Felix Frey.
As of January 1, 2019, Prof. Dr. med. dent. Daniel Buser will become Chairman of the Board of Directors of sitem-insel after Dr. h.c. Uwe E. Jocham held this position on an interim basis since autumn 2017.
Prof. Dr. Christian Leumann will newly join the strategic committee as a representative of the University of Bern. He fills the position of Dr. Daniel Odermatt, who passed away.